Eli Lilly and Company
COMPOUNDS USEFUL FOR INHIBITING RET KINASE

Abstract:

Provided herein are RET kinase inhibitors according to the formula: ##STR00001## pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use in the treatment of diseases that can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders. A, R.sub.1, n, X.sub.1, X.sub.2, X.sub.3, X.sub.4, and R.sub.2 have the meanings given in the specification.